Lessons from TGN-1412 - The impact on phase I clinical trials

IDrugs

Volumn 10, Issue 4, 2007, Pages 230-232

  Weerasekera, Natasha ^a   Hudson, Ian ^a  

^a MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; TGN 1412; UNCLASSIFIED DRUG;

BODY TEMPERATURE; CELL PROLIFERATION; CLINICAL STUDY; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE RELEASE; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; HUMAN; IMMUNOSTIMULATION; MULTIPLE ORGAN FAILURE; MYALGIA; NONHUMAN; RESPIRATORY DISTRESS; SIDE EFFECT; UNITED KINGDOM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; EUROPE; HUMANS; MACACA FASCICULARIS;

EID: 33947615289     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (0)